Article
Metabolic adaptations underpin resistance to histone acetyltransferase inhibition
2022-08-12
Abstract excerpt
Histone acetyltransferases (HAT) catalyze the acylation of lysine side chains and are implicated in diverse human cancers as both oncogenes and non-oncogene dependencies 1 . Acetyl-CoA-competitive HAT inhibitors have garnered attention as potential cancer therapeutics and the first clinical trial for this class is ongoing ( NCT04606446 ). Despite broad enthusiasm for these targets, notably including CBP/p300 and...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7057d96f-2e73-5f97-bda0-c68bcac4884e
- DOI
- 10.1101/2022.08.12.503669
